Abstract:Despite the progress made with the recent clinical use of the anticancer compound cabazitaxel, the efficacy in patients remains unsatisfactory, largely due to the high in vivo toxicity of the agent. Therefore, strategies that achieve favorable outcomes and good safety profiles will greatly expand the repertoire of this potent agent. Here, we propose a combinatorial strategy to reform the cabazitaxel agent and the use of sequential supramolecular nanoassembly with liposomal compositions to assemble a prodrug-formulated liposome, termed lipoprodrug, for safe and effective drug delivery. Reconstructing cabazitaxel with a polyunsaturated fatty acid (i.e., docosahexaenoic acid) via a hydrolyzable ester bond confers the generated prodrug with the ability to be readily integrated into the lipid bilayer of liposomes for systemic administration. The resulting lipoprodrug scaffold showed significantly sustained drug release profiles and improved pharmacokinetics in rats as well as a reduction in systemic toxicity in vivo. Notably, the lipoprodrug outperformed free cabazitaxel in terms of in vivo therapeutic efficacy in multiple separate tumor xenograft-bearing mouse models, one of which was a patient-derived xenograft model. Surprisingly, the lipoprodrug was able to reduce tumor invasiveness and reprogram the tumor immunosuppressive microenvironment by proinflammatory macrophage polarization. Our findings validate this lipoprodrug approach as a simple yet effective strategy for transforming the highly toxic cabazitaxel agent into an efficacious nanomedicine with excellent in vivo tolerability. This approach could also be applied to rescue other drugs or drug candidates that have failed in clinical trials due to poor pharmacokinetic properties or unacceptable toxicity in patients.

Improved melanoma suppression with target-delivered TRAIL and PaclitaxSel by a multifunctional nanocarrier.

Co-delivery of TRAIL and paclitaxel by fibronectin-targeting liposomal nanodisk for effective lung melanoma metastasis treatment

Combined immunochemotherapy achieving targeted co-delivery of chlorogenic acid and doxorubicin by sialic acid-modified liposomes enhances anti-cancer efficacy

Transforming a Toxic Drug into an Efficacious Nanomedicine Using a Lipoprodrug Strategy for the Treatment of Patient-Derived Melanoma Xenografts.

Targeted Delivery of Transferrin and TAT Co-Modified Liposomes Encapsulating Both Paclitaxel and Doxorubicin for Melanoma.

TfR-T12 short peptide and pH sensitive cell transmembrane peptide modified nano-composite micelles for glioma treatment <i>via</i> remodeling tumor microenvironment

Enhanced Antitumor Effect of Novel Dual-Targeted Paclitaxel Liposomes

Synthesis, Characterization, and in Vitro Evaluation of TRAIL-modified, Cabazitaxel -Loaded Polymeric Micelles for Achieving Synergistic Anticancer Therapy.

Sequential depletion of myeloid-derived suppressor cells and tumor cells with a dual-pH-sensitive conjugated micelle system for cancer chemoimmunotherapy

Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression.

Engineering Exosomes Endowed with Targeted Delivery of Triptolide for Malignant Melanoma Therapy.

Improving Drug Delivery of Micellar Paclitaxel against Non-Small Cell Lung Cancer by Coloading Itraconazole as a Micelle Stabilizer and a Tumor Vascular Manipulator.

Tumor-Targeted Chemoimmunotherapy with Immune-Checkpoint Blockade for Enhanced Anti-Melanoma Efficacy.

Nanotechnology-mediated Immunochemotherapy Combined with Docetaxel and PD-L1 Antibody Increase Therapeutic Effects and Decrease Systemic Toxicity.

Enhanced Antitumor Response Mediated by the Codelivery of Paclitaxel and Adenoviral Vector Expressing Il-12

A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor Via Systemic Administration by Taking Advantages of the Limitation of EPR Effect.

A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes.

Dual Receptor Recognizing Liposomes Containing Paclitaxel and Hydroxychloroquine for Primary and Metastatic Melanoma Treatment Via Autophagy-Dependent and Independent Pathways.

Synergistic Anticancer Effects Achieved by Co-Delivery of TRAIL and Paclitaxel Using Cationic Polymeric Micelles

Biosynthetic cell membrane vesicles to enhance TRAIL-mediated apoptosis driven by photo-triggered oxidative stress

Enhanced Anticancer Efficacy of Paclitaxel Through Multistage Tumor-Targeting Liposomes Modified with RGD and KLA Peptides